Orion Corporation completed share acquisitions
ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
30 SEPTEMBER 2026 at 9.05 EEST
Orion Corporation completed share acquisitions
The share acquisitions announced by Orion Corporation on 27 August 2026 have been completed. The Company has purchased during the time period from 1 September 2026 to 29 September 2026 through trading on regulated market organised by Nasdaq Helsinki Oy a total of 500,000 Company's own B shares at an average price per share of approximately EUR 80.98. The total purchase price paid for the shares was EUR 40,490,471.13.
After the repurchases, the Company holds a total of 768,166 own B shares corresponding to approximately 0.54% of the total number of the shares and 0.10% of the votes.
Orion Corporation
| Liisa Hurme President and CEO | Mikko Kemppainen General Counsel |
Contact person:
Mikko Kemppainen, General Counsel, Orion Corporation
tel. +358 10 426 4474
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com
Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.
